Generate Biomedicines IPO
Generate Biomedicines is developing a machine learning platform to create novel proteins and medicines on demand. The company aims to revolutionize drug discovery by using AI to generate new protein-based therapeutics that could address previously undruggable targets.
What We Know
Generate Biomedicines raised $273 million in Series B funding in 2022, bringing its total funding to over $400 million and valuing the company at approximately $2.5 billion. The company is backed by prominent investors and has formed partnerships with pharmaceutical companies to advance its generative AI platform. Despite its high valuation and innovative technology, no IPO timeline has been announced. The company continues to develop its protein generation platform and advance its therapeutic pipeline while remaining privately held.
Frequently Asked Questions
Has Generate Biomedicines had an IPO?
No, Generate Biomedicines has not had an IPO and remains a private company. Despite significant funding rounds, the company has not announced plans to go public.
When is the Generate Biomedicines IPO date?
No IPO date has been announced for Generate Biomedicines. The company continues operating privately with no confirmed timeline for public market entry. Sign up for alerts to stay informed.
How can I buy Generate Biomedicines stock?
Generate Biomedicines stock is not currently available for purchase as the company remains private. Shares may only be available through private markets or accredited investor channels. Sign up for alerts to stay informed.
Stay Updated on the Generate Biomedicines IPO
Get real-time alerts when Generate Biomedicines files for an IPO, prices shares, or begins trading.
Get IPO Alerts